MiraKind is a nonprofit organization that brings important genetic discoveries from research labs to patients, doctors and the public. Founded by Joanne Weidhaas, MD, PhD, MiraKind validates newly discovered genetic markers based on microRNA biology to determine the best clinical applications that enhance health and longevity. Our current research focuses on the KRAS-variant, an inherited, genetic marker that has significant implications for women’s health, predicting endometriosis and associated infertility, breast, ovarian and lung cancer, and unique response to agents used to treat these problems. Please visit MiraKind.org to learn more and take our study eligibility survey.

1. Awareness is great, but
ENROLL in a MiraKind
study and help find
answers for the 20%
of women with breast
cancer who carry the
KRAS-variant gene
mutation.
HELP researchers find
treatment and lifestyle
options that will make
significant strides
towards prevention
and cure for KRAS-variant
women.
THIS OCTOBER . . .
LEARN about the
increased risk for a
second, independent
cancer that is associated
with this newly found
inherited gene
mutation.
ACTION is better.
MiraKind.org